These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22362554

  • 1. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
    Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH, Glisson BS, Kim YH, Lee HY.
    Int J Cancer; 2012 Nov 15; 131(10):2253-63. PubMed ID: 22362554
    [Abstract] [Full Text] [Related]

  • 2. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1536-48. PubMed ID: 15494604
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
    Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM.
    Cancer Res; 2002 Jun 15; 62(12):3530-7. PubMed ID: 12068000
    [Abstract] [Full Text] [Related]

  • 4. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.
    PLoS One; 2010 Sep 14; 5(9):e12417. PubMed ID: 20856855
    [Abstract] [Full Text] [Related]

  • 5. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
    Jin Q, Lee HJ, Min HY, Smith JK, Hwang SJ, Whang YM, Kim WY, Kim YH, Lee HY.
    Carcinogenesis; 2014 Oct 14; 35(10):2232-43. PubMed ID: 24942865
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
    Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuoglio D.
    Mol Cancer; 2014 Oct 09; 13():230. PubMed ID: 25301686
    [Abstract] [Full Text] [Related]

  • 7. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY.
    Cancer Lett; 2015 Jun 01; 361(2):197-206. PubMed ID: 25721083
    [Abstract] [Full Text] [Related]

  • 8. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J, Guan J, Chang I, Chen X, Han D, Wang CY.
    Mol Cancer Ther; 2010 Jul 01; 9(7):1977-84. PubMed ID: 20571067
    [Abstract] [Full Text] [Related]

  • 9. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY.
    Clin Cancer Res; 2008 Mar 01; 14(5):1581-9. PubMed ID: 18316583
    [Abstract] [Full Text] [Related]

  • 10. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
    Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY.
    Blood; 2011 Sep 01; 118(9):2622-31. PubMed ID: 21551235
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 01; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K.
    Lung Cancer; 2013 Nov 01; 82(2):214-21. PubMed ID: 24051085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
    Oh SH, Kim WY, Lee OH, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY.
    Cancer Sci; 2012 Jul 01; 103(7):1259-66. PubMed ID: 22494072
    [Abstract] [Full Text] [Related]

  • 20. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y, Tong Y, Yang X, Li F, Zheng L, Liu W, Wu J, Ou R, Zhang G, Hu M, Liu Z, Lu L.
    Pharmacol Res; 2016 Sep 01; 111():113-125. PubMed ID: 27268146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.